Onsdag 18 Juni | 12:21:28 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-06 08:30 Kvartalsrapport 2025-Q3
2025-07-24 08:30 Kvartalsrapport 2025-Q2
2025-05-23 - X-dag ordinarie utdelning MNTC 0.00 SEK
2025-05-22 - Årsstämma
2025-05-08 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-07-23 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning MNTC 0.00 SEK
2024-05-23 - Årsstämma
2024-05-03 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-07-20 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning MNTC 0.00 SEK
2023-05-11 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-03 - Bokslutskommuniké 2022
2022-10-26 - Kvartalsrapport 2022-Q3
2022-07-21 - Kvartalsrapport 2022-Q2
2022-04-28 - X-dag ordinarie utdelning MNTC 0.00 SEK
2022-04-28 - Kvartalsrapport 2022-Q1
2022-04-27 - Årsstämma
2022-02-03 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-07-22 - Kvartalsrapport 2021-Q2
2021-05-07 - X-dag ordinarie utdelning MNTC 0.00 SEK
2021-05-06 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-04 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-13 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning MNTC 0.00 SEK
2020-05-27 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-25 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-08-28 - Extra Bolagsstämma 2019

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Mentice är verksamt inom medicinteknik. Bolaget utvecklar medicinska instrument för endovaskulär simulering samt för träningstillfällen inom kirurgi. Programmen är utvecklade för att användas i utbildningssyfte bland sjukhus och institut. Störst verksamhet återfinns inom Nordamerika och Europa. Utöver huvudverksamheten erbjuds möjligheter till leasing, support, samt teknisk service. Huvudkontoret ligger i Göteborg.
2025-06-16 15:58:00

Mentice AB (publ), a globally recognized leader in simulation solutions for image-guided interventional therapies, today announces the intent of a strategic workforce realignment and the intent of planning a rights issue of max 10% of the share capital aimed at optimizing its organizational structure and aligning resources with long-term business priorities.

During recent months, Mentice has made a strategic review of the company under the leadership of the new CEO Frans Venker. The purpose of the strategic review is to focus Mentice business on the strategically most important areas and to strengthen the company for the future. Mentice key strengths are within simulation and training. This review has led to the intent of a workforce realignment.

As this is a global realignment of the workforce Mentice will submit a notice of redundancies for up to 18% of the workforce to the relevant and public employment authorities. The realignment will lead to non-recurring expenses and will result in a lower cost level for the company going forward. The realignment of workforce is expected to result in annual cost savings of up to 25m SEK, with a one-time restructuring cost of approximately 5-12m SEK expected to be recognized during 2025. The changes are anticipated to be fully implemented during the year. More information will be given in the interim report for the second quarter, which is due to be published on July 24th.

“As we move forward, our focus remains on serving our customers and partners with excellence and continuing to advance our mission to improve patient outcomes through innovative high-tech simulation.” said Frans Venker, CEO of Mentice AB.  “While this has been a difficult decision, it is a necessary step to ensure that Mentice remains agile, focused, and prepared for the next phase of growth,”

Mentice customer centric operational goals will not be affected by this realignment. Customer delivery capabilities, product development initiatives, and ongoing support will remain unaffected. This ensures that Mentice high standards of service and quality are fully preserved.

Furthermore, the Board has started the process to use its mandate to make a rights issue of up to 10% of the share capital. The rights issue will strengthen the company’s financial position during the time under which the company is executing the realignment.

Mentice will continue to invest in core innovation areas and strategic customer initiatives, maintaining a clear focus on driving value for shareholders and stakeholders.